G1’s Demaree Jumps to Karyopharm for Chief Commercial Officer Job

John Demaree is joining Karyopharm Therapeutics (NASDAQ: [[ticker:KPTI]]) as its chief commercial officer, the same position he held most recently at G1 Therapeutics (NASDAQ: [[ticker:GTHX]]). His experience also includes positions at Astellas Pharma, Abbott Laboratories (NYSE: [[ticker:ABT]]), Novartis (NYSE: [[ticker:NVS]]), and Eli Lilly (NYSE: [[ticker:LLY]]). Newton, MA-based Karyopharm recently reported positive results from a Phase 3 study of multiple myeloma drug selinexor (Xpovio) that could support expansion of the drug’s approval to cover more patients.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan